{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:35:48Z","timestamp":1769826948190,"version":"3.49.0"},"reference-count":54,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Alpine Immune Sciences, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,7,18]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28 co-stimulation while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoints. The safety and efficacy of davoceticept monotherapy and davoceticept and pembrolizumab combination therapy in adult patients with advanced solid tumors were explored in NEON-1 and NEON-2, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In NEON-1 (n=58), davoceticept 0.001\u201310\u2009mg\/kg was administered intravenous either once weekly (Q1W) or once every 3 weeks (Q3W). In NEON-2 (n=29), davoceticept was administered intravenously at 2 dose levels (0.1 or 0.3\u2009mg\/kg) Q1W or Q3W with pembrolizumab (400\u2009mg once every 6 weeks). In both studies, primary endpoints included incidence of dose-limiting toxicities (DLT); type, incidence, and severity of adverse events (AEs) and laboratory abnormalities; and seriousness of AEs. Secondary endpoints included antitumor efficacy assessed using RECIST v1.1, pharmacokinetics, anti-drug antibodies, and pharmacodynamic biomarkers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The incidence of treatment-related AEs (TRAEs) and immune-related adverse events (irAEs) was 67% (39\/58) and 36% (21\/58) with davoceticept monotherapy, and 62% (18\/29) and 31% (9\/29) with davoceticept and pembrolizumab combination, respectively. The incidence of \u2265grade (Gr)3 TRAEs and \u2265Gr3 irAEs was 12% (7\/58) and 5% (3\/58) with davoceticept monotherapy, and 24% (7\/29) and 10% (3\/29) with davoceticept and pembrolizumab combination, respectively. One DLT of Gr3 immune-related gastritis occurred during davoceticept monotherapy 3\u2009mg\/kg Q3W. During davoceticept combination with pembrolizumab, two Gr5 cardiac DLTs occurred; one instance each of cardiogenic shock (0.3\u2009mg\/kg Q3W, choroidal melanoma metastatic to the liver) and immune-mediated myocarditis (0.1\u2009mg\/kg Q3W, microsatellite stable metastatic colorectal adenocarcinoma), prompting early termination of both studies. Across both studies, five patients with renal cell carcinoma (RCC) exhibited evidence of clinical benefit (two partial response, three stable disease).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Davoceticept was generally well tolerated as monotherapy at intravenous doses up to 10\u2009mg\/kg. Evidence of clinical activity was observed with davoceticept monotherapy and davoceticept in combination with pembrolizumab, notably in RCC. However, two fatal cardiac events occurred with the combination of low-dose davoceticept and pembrolizumab. Future clinical investigation with davoceticept should not consider combination with programmed death-1-inhibitor anticancer mechanisms, until its safety profile is more fully elucidated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>NEON-1 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04186637\">NCT04186637<\/jats:ext-link>) and NEON-2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT04920383\">NCT04920383<\/jats:ext-link>).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009474","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:25:16Z","timestamp":1722691516000},"page":"e009474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1\/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04186637","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04920383","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"first","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-0789","authenticated-orcid":false,"given":"Ludimila","family":"Cavalcante","sequence":"additional","affiliation":[{"name":"Emory University Winship Cancer Institute, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6327-0176","authenticated-orcid":false,"given":"Nehal","family":"Lakhani","sequence":"additional","affiliation":[{"name":"START Midwest, Grand Rapids, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-6759","authenticated-orcid":false,"given":"Justin","family":"Moser","sequence":"additional","affiliation":[{"name":"HonorHealth Research and Innovation Institute, Scottsdale, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[{"name":"Linear Clinical Research, Nedlands, Western Australia, Australia"},{"name":"The University of Western Australia, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[{"name":"Nucleus Network Ltd, Melbourne, Victoria, Australia"},{"name":"The Alfred, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":false,"given":"Rachel E","family":"Sanborn","sequence":"additional","affiliation":[{"name":"Earle A Chiles Research Institute, Portland, Oregon, USA"},{"name":"Providence Cancer Center, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet S","family":"Grewal","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute, Louisville, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajita","family":"Narayan","sequence":"additional","affiliation":[{"name":"Franciscan Physician Network with Franciscan Alliance, Lafayette, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[{"name":"START, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin F","family":"Gainor","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale University Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Enstrom","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Blanchfield","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Thomas","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Chisamore","sequence":"additional","affiliation":[{"name":"Merck & Co Inc, Rahway, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanford L","family":"Peng","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3021-6135","authenticated-orcid":false,"given":"Allison","family":"Naumovski","sequence":"additional","affiliation":[{"name":"Alpine Immune Sciences Inc, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2025100311595775000_12.8.e009474.1","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"2025100311595775000_12.8.e009474.2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"2025100311595775000_12.8.e009474.3","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"2025100311595775000_12.8.e009474.4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.7.839"},{"key":"2025100311595775000_12.8.e009474.5","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324228"},{"key":"2025100311595775000_12.8.e009474.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0931259100"},{"key":"2025100311595775000_12.8.e009474.7","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J Immunol"},{"key":"2025100311595775000_12.8.e009474.8","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"2025100311595775000_12.8.e009474.9","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6"},{"key":"2025100311595775000_12.8.e009474.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694362"},{"key":"2025100311595775000_12.8.e009474.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694363"},{"key":"2025100311595775000_12.8.e009474.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.3.561"},{"key":"2025100311595775000_12.8.e009474.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5031"},{"key":"2025100311595775000_12.8.e009474.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(94)80021-9"},{"key":"2025100311595775000_12.8.e009474.15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.3.393"},{"key":"2025100311595775000_12.8.e009474.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.016"},{"key":"2025100311595775000_12.8.e009474.17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0316"},{"key":"2025100311595775000_12.8.e009474.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7062"},{"key":"2025100311595775000_12.8.e009474.19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","article-title":"Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Cell Rep"},{"key":"2025100311595775000_12.8.e009474.20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"2025100311595775000_12.8.e009474.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2025100311595775000_12.8.e009474.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100311595775000_12.8.e009474.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100311595775000_12.8.e009474.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100311595775000_12.8.e009474.25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292"},{"key":"2025100311595775000_12.8.e009474.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114"},{"key":"2025100311595775000_12.8.e009474.27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"2025100311595775000_12.8.e009474.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80059-5"},{"key":"2025100311595775000_12.8.e009474.29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.2.523"},{"key":"2025100311595775000_12.8.e009474.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.7678351"},{"key":"2025100311595775000_12.8.e009474.31","first-page":"6477","article-title":"Specificity and longevity of antitumor immune responses induced by B7-transfected tumors","volume":"54","author":"Townsend","year":"1994","journal-title":"Cancer Res"},{"key":"2025100311595775000_12.8.e009474.32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba2325","article-title":"Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy","volume":"12","author":"Waite","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100311595775000_12.8.e009474.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29286-5","article-title":"The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity","volume":"13","author":"Maurer","year":"2022","journal-title":"Nat Commun"},{"key":"2025100311595775000_12.8.e009474.34","first-page":"5713","article-title":"Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab","volume":"37","author":"Haratake","year":"2017","journal-title":"Anticancer Res"},{"key":"2025100311595775000_12.8.e009474.35","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jtho.2019.05.026","article-title":"Extrinsic upregulation of PD-L1 induced by pembrolizumab combination therapy in patients with NSCLC with low tumor PD-L1 expression","volume":"14","author":"Kunimasa","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025100311595775000_12.8.e009474.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2025100311595775000_12.8.e009474.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100311595775000_12.8.e009474.38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"JOP"},{"key":"2025100311595775000_12.8.e009474.39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature New Biol"},{"key":"2025100311595775000_12.8.e009474.40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683"},{"key":"2025100311595775000_12.8.e009474.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401686"},{"key":"2025100311595775000_12.8.e009474.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806075105"},{"key":"2025100311595775000_12.8.e009474.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020"},{"key":"2025100311595775000_12.8.e009474.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"2025100311595775000_12.8.e009474.45","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100311595775000_12.8.e009474.46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100311595775000_12.8.e009474.47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0856"},{"key":"2025100311595775000_12.8.e009474.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00244-8"},{"key":"2025100311595775000_12.8.e009474.49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030242"},{"key":"2025100311595775000_12.8.e009474.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"2025100311595775000_12.8.e009474.51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0218"},{"key":"2025100311595775000_12.8.e009474.52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","article-title":"Preliminary results from a phase 1\/2 study of co-stimulatory bispecific psmaxcd28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc)","volume":"41","author":"Stein","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100311595775000_12.8.e009474.53","unstructured":"Regeneron reports second quarter 2023 financial and operating results. GlobeNewswire; 2023."},{"key":"2025100311595775000_12.8.e009474.54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138729","article-title":"CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation","volume":"5","author":"Beckermann","year":"2020","journal-title":"JCI Insight"}],"updated-by":[{"DOI":"10.1136\/jitc-2024-009474corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:00:07Z","timestamp":1759518007000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/jitc-2024-009474"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009474","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jitc-2024-009474corr1","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}